Clin2
NCT06431685Possibly a fitRecruiting

Brain radiation, immunotherapy, and chemo for lung cancer spread

NSCLCLow Dose RadiotherapyPD-1 InhibitorLeptomeningeal Metastasis

Treatments studied

Part of Brain & nervous system, Cancer clinical trials.

This trial tests a combination of low-dose radiation to the whole brain, immunotherapy, and chemotherapy given through a lumbar puncture. It is for people with lung cancer that has spread to the lining of the brain and has not responded to standard treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
10 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have lung cancer that has spread to the lining of the brain or spinal cord (leptomeningeal metastasis).
  • Standard treatments for your lung cancer have stopped working.
  • Your cancer outside the brain is not growing (stable disease).
  • You are willing to undergo radiation to the brain, immunotherapy, and chemotherapy via lumbar puncture.
  • You do not have an active autoimmune disease or serious health problems like uncontrolled heart or kidney failure.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06663306Recruiting· Phase 1
Intrathecal pemetrexed and bevacizumab for lung cancer brain spread

This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.

Shanghai
NCT07398599Recruiting
Double-dose targeted therapy plus chemo for lung cancer spread to brain lining

This trial tests a stronger dose of an EGFR-targeted drug combined with bevacizumab and chemotherapy into the spinal fluid for patients with non-small cell lung cancer that has spread to the lining of the brain and is no longer responding to standard treatment.

Nanchang, Jiangxi
NCT07778940Not yet recruiting· Phase 2
Chemotherapy through a brain port for lung cancer that has spread to the spinal fluid

This trial tests a chemotherapy drug called thiotepa, given through a small device placed under the scalp (Ommaya reservoir) that delivers the drug directly into the spinal fluid. It is for people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord and who have stopped responding to certain targeted therapies.

Tianjin
NCT06901817Recruiting· Phase 2
Study of pemetrexed plus nivolumab for lung cancer that has spread to the lining of the brain

This trial tests a combination of two drugs, pemetrexed and nivolumab, given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (non-squamous non-small cell) that has spread to the lining of the brain and has not responded to other treatments.

Shanghai, Shanghai Municipality
NCT06296745Recruiting· Phase 2
Pemetrexed in spinal fluid for lung cancer that spread to brain lining

This trial tests a drug called pemetrexed, given directly into the fluid around the spinal cord (intrathecal), for people with lung cancer that has spread to the brain and spinal cord lining and is no longer controlled by the targeted therapy osimertinib.

Huizhou, Guangdong
NCT06132698Recruiting· Phase 2
Immunotherapy injected into spinal fluid for lung cancer that has spread to the brain lining

This trial tests giving an immunotherapy drug directly into the spinal fluid for people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord. The goal is to see if this approach can help control the cancer while allowing you to continue other treatments you may already be taking.

Chengdu, Sichuan

Hear when a new PD-1 Inhibitor trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.